-
1.发明公开PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 审中-公开吡啶并[3,4-d]嘧啶衍生物和药物可接受的盐
公开(公告)号：EP3305785A1
公开(公告)日：2018-04-11
申请号：EP16803266.2
申请日：2016-05-27
发明人： MIZUNO, Tsuyoshi , SHIMADA, Tomohiro , UNOKI, Gen , EBISAWA, Masaru , TAKEUCHI, Susumu , MINAMIZONO, Kunio , SASAKI, Kosuke , YOKOSAKA, Takuya , IGARASHI, Junji , MARUYAMA, Akinobu , TAKAHASHI, Hiroshi , HORIE, Kyohei , SAKAI, Yuri
IPC分类号： C07D471/04 , A61K31/519 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/553 , A61P9/10 , A61P11/00 , A61P19/02 , A61P25/28 , A61P29/00 , A61P35/00 , A61P43/00 , C07D519/00
CPC分类号： A61K31/519 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/553 , A61P9/10 , A61P19/02 , A61P35/00 , C07D471/04 , C07D519/00
摘要： The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明的目的是提供具有优异的CDK4 / 6抑制活性的化合物。 本发明是由通式（I）表示的化合物或其药学上可接受的盐。
-
公开(公告)号：EP2944633B1
公开(公告)日：2018-01-31
申请号：EP13854714.6
申请日：2013-11-13
发明人： MARUYAMA, Akinobu , KAMADA, Hirofumi , FUJINUMA, Mika , TAKEUCHI, Susumu , SAITOH, Hiroshi , TAKAHASHI, Yoshimasa
IPC分类号： C07D401/04 , A61K31/4439 , A61P3/10 , A61P9/10 , A61P9/12 , A61P13/12 , A61P43/00 , C07D409/14
CPC分类号： C07D409/14 , A61K31/4439 , C07D401/04 , C07D401/12 , C07D401/14 , C07D491/048 , A61K2300/00
摘要： Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.
-
公开(公告)号：EP4137481A1
公开(公告)日：2023-02-22
申请号：EP21789367.6
申请日：2021-04-15
发明人： SUGIYAMA, Sakae , YOKOSAKA, Takuya , MINAMIZONO, Kunio , KAWANA, Asahi , KANEKO, Toshiyuki , MARUYAMA, Akinobu , SASAKI, Kosuke , HOSODA, Shinnosuke , KOSHIMIZU, Masaki , TAKEUCHI, Susumu , KATO, Kenta , CHAKKA, Nagasree , JOHNSON, Brett M. , WHITE, Ryan d. , ZHAO, Wei
IPC分类号： C07D213/74 , A61K31/427 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/551 , A61P3/10 , A61P7/10 , A61P9/04 , A61P9/12 , A61P11/00 , A61P13/12 , A61P21/04 , A61P31/04 , A61P35/00 , A61P43/00 , C07D237/20 , C07D239/34 , C07D239/42
摘要： A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar 1 , Ar 2 , X 1 -X 3 , R 1 , R 3 , R 7 , R 8 , L 1 , and L 2 are as defined in the specifications.)
-
公开(公告)号：EP3546458A1
公开(公告)日：2019-10-02
申请号：EP17874165.8
申请日：2017-11-27
发明人： MIZUNO, Tsuyoshi , SHIMADA, Tomohiro , UNOKI, Gen , MARUYAMA, Akinobu , SASAKI, Kosuke , YOKOSAKA, Takuya , TAKAHASHI, Hiroshi , HORIE, Kyohei , SAKAI, Yuri
IPC分类号： C07D471/04 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/553 , A61P9/10 , A61P11/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D519/00
摘要： The purpose of the present invention is to provide a compound that has excellent CDK4/6 inhibitory activity. The present invention is a compound represented by formula (I) or a pharmaceutically acceptable salt of the compound.
-
公开(公告)号：EP3339302A1
公开(公告)日：2018-06-27
申请号：EP18152142.8
申请日：2013-11-13
发明人： MARUYAMA, Akinobu , KAMADA, Hirofumi , FUJINUMA, Mika , TAKEUCHI, Susumu , SAITOH, Hiroshi , TAKAHASHI, Yoshimasa
IPC分类号： C07D401/04 , A61K31/4439 , A61P3/10 , A61P9/10 , A61P9/12 , A61P13/12 , A61P43/00 , C07D409/14
CPC分类号： C07D409/14 , A61K31/4439 , C07D401/04 , C07D401/12 , C07D401/14 , C07D491/048 , A61K2300/00
摘要： Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.
-
公开(公告)号：EP3144306B1
公开(公告)日：2017-11-15
申请号：EP15792266.7
申请日：2015-05-12
IPC分类号： C07D403/04 , A61K31/497 , A61P3/10 , A61P9/10 , A61P9/12 , A61P13/12 , A61P19/06 , A61P43/00 , C07D403/14 , C07D409/14
CPC分类号： C07D403/04 , A61K31/497 , C07D401/14 , C07D403/14 , C07D409/14
摘要： Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.
-
公开(公告)号：EP3144306A1
公开(公告)日：2017-03-22
申请号：EP15792266.7
申请日：2015-05-12
IPC分类号： C07D403/04 , A61K31/497 , A61P3/10 , A61P9/10 , A61P9/12 , A61P13/12 , A61P19/06 , A61P43/00 , C07D403/14 , C07D409/14
CPC分类号： C07D403/04 , A61K31/497 , C07D401/14 , C07D403/14 , C07D409/14
摘要： Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.
摘要翻译： 提供下式（I）表示的新型吡嗪衍生物或其药学上可接受的盐或其溶剂化物，其用于治疗或预防URAT1所涉及的疾病，包括痛风，高尿酸血症，高血压，肾病如 间质性肾炎等，糖尿病，动脉硬化，Lesch-Nyhan综合征等。
-
8.发明公开NOVEL CRYSTALLINE POLYMORPH OF PYRIDINE DERIVATIVE, AND METHOD FOR PRODUCING SAME 审中-公开新型的多晶型其制造吡啶和方法
公开(公告)号：EP3144304A1
公开(公告)日：2017-03-22
申请号：EP15792728.6
申请日：2015-05-12
IPC分类号： C07D401/04 , A61K31/4439 , A61P3/10 , A61P9/10 , A61P9/12 , A61P13/12 , A61P19/06 , A61P43/00
CPC分类号： C07D401/04 , A61K31/4439 , C07B2200/13
摘要： Disclosed are crystals of 2-(5-chloropyridin-3-yl)-1-(2,5-dichlorobenzyl)-4-methyl-1H-imidazole-5-carboxylic acid useful as therapeutic or prophylactic agents for gout, hyperuricemia, and the like, and a method for producing the crystals.
摘要翻译： 所公开的是晶体2-（5-氯吡啶-3-基）-1-（2,5-二氯苄基）-4-甲基-1H-咪唑-5-甲酸，为痛风，高尿酸血症的治疗或预防剂是有用的，并 等，并且用于制造晶体的方法。
-
公开(公告)号：EP2944633A1
公开(公告)日：2015-11-18
申请号：EP13854714.6
申请日：2013-11-13
发明人： MARUYAMA, Akinobu , KAMADA, Hirofumi , FUJINUMA, Mika , TAKEUCHI, Susumu , SAITOH, Hiroshi , TAKAHASHI, Yoshimasa
IPC分类号： C07D401/04 , A61K31/4439 , A61P3/10 , A61P9/10 , A61P9/12 , A61P13/12 , A61P43/00 , C07D409/14
CPC分类号： C07D409/14 , A61K31/4439 , C07D401/04 , C07D401/12 , C07D401/14 , C07D491/048 , A61K2300/00
摘要： Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.021 秒)
